Anti-interleukin 5 monoclonal antibody/anti-interleukin 5Rα monoclonal antibody in severe eosinophilic asthma

Abstract

Adjunctive therapy with monoclonal antibodies to IL-5/IL-5Ra in the treatment of refractory non-atopic eosinophilic asthma is a clear benefit. It leads to disease control, reducing the number of acute exacerbations, improving lung function, and reducing systemic corticotherapy, resulting in improved quality of life.

Keywords

• severe eosinophilic asthma
• blood eosinophilic count
• interleukin 5
• IL-5/IL-5Ra antibodies